<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app19.us.archive.org';v.server_ms=672;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml', '20171002223804')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171002223804/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171002223804/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171002223804" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930191124/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 22:38:04 Oct 02, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930191124/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml" title="19:11:24 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 22:38:04 Oct 02, 2017">02</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930191124/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 22:38:04 Oct 02, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171002223804*/https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 02 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-9296?contentType=xml","2017-10-02",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>United Kingdom national guideline for gonorrhoea testing 2012.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Clinical Effectiveness Group. United Kingdom national guideline for gonorrhoea testing 2012. London (UK): British Association for Sexual Health and HIV (BASHH); 2012. 13 p.  [51 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Ison C, Jungmann E, Bignell C. Gonorrhoea. In: Ross J, Ison C, Carder C, Lewis D, Mercey D, Young H. Sexually transmitted infections: UK national screening and testing guidelines. London (UK): British Association for Sexual Health and HIV (BASHH); 2006 Aug. p. 16-25.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note from the British Association of Sexual Health and HIV (BASHH)</strong>: This guideline complements the 2010 Health Protection Agency (HPA) document Guidance for gonorrhoea testing in England and Wales. This guideline should be read in conjunction with the BASHH United Kingdom (UK) national guideline for the management of gonorrhoea in adults 2010.</p>
<p>Definitions for the level of evidence (<strong>I-IV</strong>) and grade of recommendation (<strong>A-C</strong>) are provided at the end of the &quot;Major Recommendations&quot; field.</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Major Changes in 2012 Guideline&quot;>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>
            <p><strong>Major Changes in 2012 Guideline</strong></p>
            <p>Significant developments since the publication of the previous guideline in 2006 include:</p>
            <ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
                <li>Nucleic acid amplification tests (NAATs) are now used in many clinical services for detecting <em>Neisseria gonorrhoeae</em> and widespread clinical experience has been gained with these tests. </li>
                <li>New NAATs with different nucleic acid targets and improved sensitivity and specificity have been developed and licensed; the Health protection Agency (HPA) has published guidance for gonorrhoea testing in England and Wales and the Health Protection Scotland (HPS) similar guidance in Scotland. </li>
                <li>There have been clinical reports of treatment failures using many recommended treatments for gonorrhoea and increasing concern about reduced sensitivity of <em>N. gonorrhoeae</em> to third generation cephalosporins. </li>
            </ol>
            </td>
        </tr>
    </tbody>
</table>
<p>&amp;nbsp;</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Major New Recommendations&quot;>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>
            <p><strong>Major New Recommendations</strong></p>
            <ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
                <li>NAATs are the test of choice for testing asymptomatic individuals for urethral or endocervical infection with <em>N. gonorrhoeae</em>. </li>
                <li>NAATs are the test of choice for testing rectal and pharyngeal infection in men who have sex with men (MSM). </li>
                <li>Positive NAATs from extragenital sites and low prevalence populations need confirmation by supplementary testing that uses a different nucleic acid target. </li>
                <li>The re-introduction of test of cure is recommended as part of the routine follow-up of patients treated for gonorrhoea. </li>
                <li>Testing by culture remains essential where infection persists after treatment and treatment failure is suspected. </li>
            </ol>
            </td>
        </tr>
    </tbody>
</table>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Recommended Tests</span></strong></p>
<p>No test offers 100% sensitivity and specificity and the prevalence of gonorrhoea in many genitourinary and sexual health clinics is less than 1%. The prevalence may vary between subgroups of patients even within the same clinic. The testing methodology used should give a positive predictive value (PPV) exceeding 90%. Laboratories used for testing should be appropriately accredited by a nationally approved accreditation scheme, notably by Clinical Pathology Accreditation (UK) Ltd (CPA) or equivalent.</p>
<p>There are two principal ways to detect <em>N. gonorrhoeae</em> &amp;ndash; by detection of amplified nucleic acid and by culture. <em>N. gonorrhoeae</em> can also be visualized by microscopy of Gram stained specimens from the ano-genital mucosae which can be used to facilitate rapid diagnosis in symptomatic patients.</p>
<p><strong>Recommendations</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Nucleic acid amplification tests (NAATs) are the recommended tests for urine in men, non-invasively collected samples (e.g., vulvovaginal swab) and for identifying rectal and pharyngeal infection in men-who-have-sex-with-men (MSM) (<strong>IIa, B</strong>). For endocervical and urethral specimens, NAATs offer higher sensitivity and less demanding specimen handling than culture but deny the opportunity for antimicrobial sensitivity testing. </li>
    <li>Culture remains a sensitive test for clinician taken genital specimens and is essential for patients with persisting symptoms or signs after treatment to exclude antimicrobial resistance. </li>
    <li>Microscopy of Gram-stained endocervical and urethral smears has low (40-60%) sensitivity in screening asymptomatic patients and is not recommended for routine practice. </li>
    <li>A culture should be taken in all cases of gonorrhoea diagnosed by NAAT's prior to antibiotics being given, if possible, so that susceptibility testing can be performed and resistant strains identified. </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Recommended Sites for Testing</span></strong></p>
<p>Mucosal sites associated with symptoms (discharge and/or pain) or signs (discharge and/or inflammation) should be tested for <em>N. gonorrhoeae</em>.</p>
<p><strong>Screening</strong></p>
<p>Current clinical practice in the United Kingdom (UK) for screening asymptomatic heterosexual individuals for gonorrhoea utilizes a single test and the sensitivity and convenience of NAATs: a first pass urine is collected from men and a vulvovaginal swab (which may be self taken) from women. Urine can be used in women but is sub-optimal. There is no data to confirm the adequacy of this approach. Culture testing in women identified the urethra as the only site of infection in 6%. Sampling the endocervix and urethra continues to be recommended when testing women by culture. There is little recent data quantifying the additional contribution of routinely taking rectal and pharyngeal specimens when screening women, although sampling should be considered at these sites where there is a history of direct exposure. There are no data on the minimum incubation period necessary to exclude infection but it is pragmatic to align it with the recommendation for chlamydia: that a test should be done when the patient presents and if the exposure was within the last two weeks, repeated two weeks after exposure.</p>
<p><em>Endocervix</em></p>
<p>In women, the endocervix is the principal site sampled, either directly during speculum examination or indirectly by a vulvovaginal swab. Samples taken directly from the endocervix are suitable for culture, NAATs and microscopy. Water based gel lubricants that are sterile and do not contain bacteriostatic or bactericidal additives appear not to affect cultures or NAATs for <em>N. gonorrhoeae</em>.</p>
<p><em>Urethra</em></p>
<p>In men, the urethra is the principal site sampled, either directly from the urethral meatus or indirectly in a first pass urine sample. Samples directly taken from the urethra are suitable for microscopy, culture and NAATs. For sampling, a loop or cotton-tipped swab is introduced 1 to 2 cm into the urethral orifice. A higher sensitivity for microscopy is reported for urethral samples taken with a plastic loop compared to those taken with a cotton-tipped swab.</p>
<p>In women, sampling the urethra is only recommended to complement testing with endocervical culture and after hysterectomy.</p>
<p><em>Rectum</em></p>
<p>Rectal testing should be dictated by symptoms and history of direct sexual exposure. The rectum can be sampled by culture and NAATs. NAATs offer significantly enhanced sensitivity compared with culture in MSM and are the test of choice in this patient population. Confirmatory testing is recommended for positive results. The use of NAATs on rectal samples may require local validation to comply with CPA accreditation. Anorectal samples from patients without symptoms may be obtained by blindly passing a moist swab 2 to 4 cm into the anal canal, using lateral pressure to try and avoid any faecal mass (<strong>IIIB</strong>). Swabs with heavy faecal contamination should be discarded. In symptomatic patients, proctoscopy may aid diagnosis and allow specimens to be obtained under direct vision. Obtaining smears under direct vision improves the low sensitivity of microscopy (<strong>IIIC</strong>) to aid immediate diagnosis.</p>
<p><em>Oropharynx</em></p>
<p>Oropharyngeal testing should be dictated by symptoms and history of direct sexual exposure. For men, the pharynx should be sampled if the man has been the active provider of fellatio, but not if he is only the active provider of cunnilingus. Specimens are obtained by wiping a swab over the posterior pharynx, tonsils, and tonsillar crypts. Samples can be tested by culture (although sensitivity is low) and NAATs. NAATs are not approved for testing for <em>N. gonorrhoeae</em> in the pharynx but offer significantly enhanced sensitivity compared with culture in MSM and other high risk individuals. They are the test of choice in these patient populations and confirmatory testing is recommended for positive results. The use of NAATs on pharyngeal samples may require local validation to comply with CPA accreditation.</p>
<p><em>Urine</em></p>
<p>Urine is an easily obtained non-invasive sample and is the sample of choice when testing asymptomatic men using a NAAT. The first 15 to 30 mls of urine is collected after urine has been held for at least an hour. Urine is not suitable for culture. In women, the sensitivity of urine testing by NAATs is lower than vulvovaginal or endocervical swabs and urine is not a specimen of choice in women (<strong>IIB</strong>).</p>
<p><em>Vagina</em></p>
<p>Patient-taken vulvovaginal swabs and clinician-taken endocervical swabs are equally suitable for detecting <em>N. gonorrhoeae</em> when tested by NAATs. Vulvovaginal swabs are the sample of choice for screening asymptomatic women for gonorrhoea.</p>
<p><em>Neisseria gonorrhoeae</em> may infect the vaginal mucosa of prepubertal girls because the vagina is lined with columnar epithelium in pre-pubertal girls. Vaginal samples should be cultured in these circumstances in view of the implications of the diagnosis and to provide diagnostic certainty.</p>
<p><em>Bartholin's Duct</em></p>
<p>When a Bartholin's abscess is present, purulent material expressed from the duct may be cultured and stained for microscopy.</p>
<p><em>Ophthalmic and Systemic Sites</em></p>
<p>Ophthalmic samples are suitable for culture. Specimens are obtained after cleaning excess exudates by wiping a swab over the lower eye lid. NAATs are not licensed for this site and there is no data to validate their use on the conjunctiva.</p>
<p>Proving infection in patients with suspected disseminated gonococcal infection (DGI) can be difficult. The diagnosis of DGI is made on the basis of positive blood or synovial culture or, in a patient with the typical clinical syndrome and negative blood or synovial culture results, on the basis of gonococci isolated from another site. Genital and pharyngeal samples should be taken and have a higher yield in identifying the presence of <em>N. gonorrhoeae</em> than blood cultures (<strong>IIIC</strong>).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Factors Which Alter Tests Recommended or Sites Tested</span></strong></p>
<p><strong>Sexual History</strong></p>
<p>Testing in heterosexual men and women focuses on the genital tract. Infection may be asymptomatic and all sexually active heterosexuals requesting screening for sexually transmitted infection at a genitourinary medicine clinic should receive a genital tract test for gonorrhoea. The prevalence of pharyngeal infection in patients attending genitourinary clinics in the UK is believed to be low and there is no evidence to support routine pharyngeal testing of heterosexuals who disclose oro-genital sexual activity. Data from a high-risk female population in the Netherlands show a prevalence of isolated pharyngeal infection of &amp;lt;0.3%. Rectal testing in women practicing anal sex is indicated in the presence of symptoms consistent with rectal infection and after sexual assault with anal penetration. The additional contribution of a rectal test to a vulvovaginal or endocervical NAAT to determine the infection status of asymptomatic women is small even in a high-risk population. A history of condom use for intercourse is not an indication to omit testing for gonorrhoea.</p>
<p><strong>Risk Groups</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Men who have sex with men
    <p>Tests should be taken from all sites (urethra, rectum, and oropharynx) potentially exposed to infection as directed by the sexual history (<strong>recommendation C</strong>). Rectal infection may be acquired by transmission from the oropharynx in the absence of penetrative anal intercourse.</p>
    </li>
    <li>Sex workers
    <p>Test all sites potentially exposed to infection as indicated by sexual history. A history of condom use should not deter testing at exposed sites.</p>
    </li>
    <li>'Young' patients
    <p>Testing in post-pubertal young men and women follows that in adults. Young people may be intimidated by the prospect of invasive tests and may prefer non-invasive options when available, notably urine testing. Cultures and implementation of chain of evidence should be considered if there is prospect of legal proceedings for sexual abuse.</p>
    </li>
</ul>
<p><strong>Other Groups</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Pregnant women
    <p>Screening tests as for heterosexual women.</p>
    </li>
    <li>Women with history of hysterectomy
    <p>A urethral swab for culture offers a better yield than high vaginal culture. No comparative data was found on testing urine, urethral swab, and vaginal swabs by NAATs.</p>
    </li>
    <li>Patients who are known contacts of gonorrhoea
    <p>Test all sites potentially exposed to infection as indicated by the sexual history. Microscopy may be worthwhile even if the patient is asymptomatic.</p>
    </li>
</ul>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Recommendation for Frequency of Repeat Testing in an Asymptomatic Patient</span></strong></p>
<p>The minimum time interval between exposure and when to test for gonorrhoea has not been determined (see above). Symptoms may develop within a few days and the incubation period for detection by culture is said to be 2 to 7 days.</p>
<p>Repeat testing should relate to risk rather than to a prescribed frequency. The prevalence of gonorrhoea in the general population is low but there are linked population subgroups at higher risk of infection and re-infection. The chance of contracting gonorrhoea depends largely on membership or contact with these subpopulations. A past history of gonorrhoea is a strong risk factor for re-infection. Re-infection rates of 0 to 30.8% have been reported in follow-up studies and about a third of patients with gonorrhoea in England and Wales have a history of previous infection. There is no compelling evidence to support frequent checks in sex workers, who have almost universal condom use at work. No general recommendation on the frequency of repeat testing in asymptomatic patients is suggested. Sexual health checks in relation to new risk exposures are self-evident and commended.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Recommendation for Test of Cure</span></strong></p>
<p>Progressive creep in minimal inhibitory concentration (MIC) to cephalosporins and reported treatment failures with ceftriaxone and cefixime indicate that microbiological cure can no longer be presumed with currently recommended treatments. Test of cure is recommended following treatment for all gonococcal infections (<strong>IVC</strong>). This is to identify treatment failure, emerging resistance which is predicted to occur on the basis of the past capability/history of <em>N. gonorrhoeae</em> and because susceptibility results that indicate potential failure to ceftriaxone and cefixime are not yet defined.</p>
<p>Where resource or practical considerations require test of cure to be selective rather than universal, then the following patients should be prioritized &amp;ndash;</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Persisting symptoms or signs </li>
    <li>Pharyngeal infection (all treatments are less effective at eradicating pharyngeal infection) </li>
    <li>Treatment with anything other than the first-line recommendations </li>
    <li>Pregnant women </li>
</ul>
<p><strong>Method and Timing of Test of Cure</strong></p>
<p>There is a lack of evidence on optimal timing for test of cure and method of testing. Current opinion and pragmatic considerations suggest that where there are persisting symptoms or signs, testing with culture should be performed at least 72 hours after completion of therapy.</p>
<p>If asymptomatic, test with NAAT's where available followed by culture if positive. Test two weeks after completion of antibiotic therapy.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong>:</p>
<p><strong>Level of Evidence</strong></p>
<p><strong>Ia</strong> Meta-analysis of randomised controlled trials</p>
<p><strong>Ib</strong> At least one randomised controlled trial</p>
<p><strong>IIa</strong> At least one well designed controlled study without randomisation</p>
<p><strong>IIb</strong> At least one other type of well-designed quasi-experimental study</p>
<p><strong>III</strong> Well designed non-experimental descriptive studies</p>
<p><strong>IV</strong> Expert committee reports or opinions of respected authorities</p>
<p><strong>Grading of Recommendation</strong></p>
<ol style=&quot;list-style-type: upper-alpha;&quot;>
    <li>Evidence at level Ia or Ib </li>
    <li>Evidence at level IIa, IIb, III </li>
    <li>Evidence at level IV </li>
</ol></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Gonorrhoea</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Risk Assessment"/>
      <fieldvalue value="Screening"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Infectious Diseases"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Pathology"/>
      <fieldvalue value="Urology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Allied Health Personnel"/>
      <fieldvalue value="Clinical Laboratory Personnel"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
      <fieldvalue value="Public Health Departments"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>To offer recommendations on gonorrhoea testing for use in specialist sexual health clinics in the United Kingdom (UK) </li>
    <li>To provide principles applicable to other healthcare settings where screening or testing for <em>Neisseria gonorrhoeae</em> is undertaken </li>
</ul>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Individuals in the United Kingdom with or at risk for gonorrhoea</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Nucleic acid amplification tests (NAATs) </li>
    <li>Culture for <em>Neisseria gonorrhoeae</em> </li>
    <li>Microscopy for intracellular Gram-negative diplococci </li>
    <li>Confirmatory testing of positive NAATs from extragenital sites and low prevalence populations </li>
    <li>Sampling by loop or cotton-tipped swab culture of mucosal sites, as appropriate, including endocervix, urethra, rectum, oropharynx, urine, vagina, Bartholin's duct, and ophthalmic and systemic sites </li>
    <li>Special considerations for testing of heterosexual women, heterosexual men, men who have sex with men, women who have had a hysterectomy, 'young' men and women, pregnancy, sex workers, victims of sexual assault, and sexual contacts of individuals with gonococcal infection </li>
    <li>Frequency of repeat testing in asymptomatic patients </li>
    <li>Patient assessment after treatment, including test of cure </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Test sensitivity and specificity </li>
    <li>Test positive predictive value (PPV) </li>
    <li>Prevalence of gonorrhoea</li>
    <li>Re-infection rate </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To update this guideline, a Medline search was conducted using the terms &quot;gonorrhoea AND testing&quot;, &quot;gonorrhoea AND diagnosis&quot;, and &quot;gonorrhoea AND screening&quot; covering the period January 2006 to December 2010. Duplicates were removed and titles and abstracts in the English language were screened (663). Full articles testing for gonorrhoea in-vitro and in clinical trials were obtained and reviewed. The Cochrane collaboration databases (<a href=&quot;http://www.cochrane.org&quot; title=&quot;Cochrane Web site&quot;>www.cochrane.org</a>) and the Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) treatment guidelines 2010 (<a href=&quot;http://www.cdc.gov/std&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;>www.cdc.gov/std</a>) were reviewed.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Level of Evidence</strong></p>
<p><strong>Ia</strong> Meta-analysis of randomised controlled trials</p>
<p><strong>Ib</strong> At least one randomised controlled trial</p>
<p><strong>IIa</strong> At least one well designed controlled study without randomisation</p>
<p><strong>IIb</strong> At least one other type of well-designed quasi-experimental study</p>
<p><strong>III</strong> Well designed non-experimental descriptive studies</p>
<p><strong>IV</strong> Expert committee reports or opinions of respected authorities</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Guideline development is undertaken by a multi-disciplinary writing committee with membership determined in a transparent manner. The chair is chosen by the Clinical Effectiveness Group (CEG). The CEG lead then discusses with the chair what suggestions they might have for members from other disciplines. The additional members of the group are then invited by the CEG. Writing committee membership includes relevant professional groups (for example, genitourinary medicine physicians, nurses, health advisors, pharmacists, microbiologists, and other professionals from allied specialties as appropriate) and when relevant this will involve working with the appropriate British Association for Sexual Health and HIV (BASHH) Special Interest Group (SIG) and the BASHH audit group.</p>
<p>This guideline was developed with involvement of the Bacterial Special Interest Group of BASHH, a group of clinicians and microbiologists with an interest in sexually-transmitted infections (STIs). There was no patient or public involvement.</p>
<p>Recommendations are formulated with consideration of their health benefits, side effects and risks, with evidence presented in the guideline that these issues have been addressed. Each recommendation is linked to the supporting evidence with a list of relevant references in the original guideline document.</p>
<p>Consideration is given to pragmatic and organisational issues relevant to the guideline. This is sought during and may emerge from the piloting of the guideline.</p>
<p>The authors consider the financial cost implications of recommendations made. Where disagreement arises within the writing committee with regard to recommendations the chair attempts to resolve these (for example by a voting system or formal consensus method). The process is documented and reported to the CEG editor. When this is not possible the CEG will review the evidence.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Grading of Recommendation</strong></p>
<ol style=&quot;list-style-type: upper-alpha;&quot;>
    <li>Evidence at level Ia or Ib </li>
    <li>Evidence at level IIa, IIb, III </li>
    <li>Evidence at level IV </li>
</ol></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The guideline was posted on the British Association of Sexual Health and HIV (BASHH) website for 3 months for consultation and comments taken into account by the authors and the Clinical Effectiveness Group (CEG) in preparing the final version.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Accurate diagnosis of gonorrhea</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Audit Criteria/Indicators"/>
      <fieldvalue value="Patient Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Clinical Effectiveness Group. United Kingdom national guideline for gonorrhoea testing 2012. London (UK): British Association for Sexual Health and HIV (BASHH); 2012. 13 p.  [51 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2006 Aug (revised 2012)"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="British Association for Sexual Health and HIV - Medical Specialty Society"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>No specific or external funding was sought or provided in the development of this guideline.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Clinical Effectiveness Group (CEG)</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Principal Authors</em>: Chris Bignell, Consultant Physician in Genitourinary Medicine, Nottingham University Hospitals NHS Trust; Catherine Ison, Professor of Microbiology, STBRL, Health Protection Agency, UK; Mark FitzGerald, Lead Editor, Consultant Physician in Genitourinary Medicine, Musgrove Park Hospital, Taunton</p>
<p><em>Clinical Effectiveness Group (CEG) Members</em>: Dr Keith Radcliffe (<em>Chair</em>), Consultant Physician in Genitourinary Medicine Whittall Street Clinic; Dr David Daniels, West Middlesex University Hospitals NHS Trust, Sexual Health Clinic West Middlesex Hospital, Isleworth; Dr Mark FitzGerald, Consultant Physician in Genitourinary Medicine, Musgrove Park Hospital, Taunton; Dr Margaret Kingston, Consultant Physician in GU Medicine, Manchester Centre for Sexual Health, The Hathersage Centre, Manchester; Dr Neil Lazaro, Associate Specialist in GU Medicine, Royal Preston Hospital, Preston; Dr Gill McCarthy, Consultant Physician in GU Medicine, Kingston Hospital NHS Trust, Wolverton Centre for Sexual Health, Kingston Upon Thames; Dr Ann Sullivan, Consultant Physician in Genitourinary Medicine, Chelsea &amp;amp; Westminster Healthcare NHS Trust, John Hunter Clinic</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Each of the authors has declared they have no conflict of interest.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Ison C, Jungmann E, Bignell C. Gonorrhoea. In: Ross J, Ison C, Carder C, Lewis D, Mercey D, Young H. Sexually transmitted infections: UK national screening and testing guidelines. London (UK): British Association for Sexual Health and HIV (BASHH); 2006 Aug. p. 16-25.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.bashh.org/documents/4490.pdf&quot; title=&quot;British Association for Sexual Health and HIV Web Site&quot;>British Association for Sexual Health and HIV Web Site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>British Association for Sexual Health and HIV: framework for guideline development and assessment. London (UK): British Association for Sexual Health and HIV; 2010. 18 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.bashh.org/documents/2926.pdf&quot; title=&quot;British Association for Sexual Health and HIV Web site&quot;>BASHH Web site</a>. </li>
</ul>
<p>Additionally, auditable outcome measures can be found in the <a href=&quot;http://www.bashh.org/documents/4490.pdf&quot; title=&quot;British Association for Sexual Health and HIV Web site&quot;>original guideline document</a>.</p></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>A guide to gonorrhoea. Patient information leaflet. London (UK): British Association for Sexual Health and HIV; 2012 Jan. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.bashh.org/documents/4237.pdf&quot; title=&quot;British Association for Sexual Health and HIV Web site&quot;>British Association for Sexual Health and HIV (BASHH) Web site</a>. </li>
    <li>A BASHH guide to gonorrhoea. Gonorrhoea - the basics. Electronic copies: Available from the <a href=&quot;http://www.bashh.org/BASHH/Public___patient_information/Information_on_STIs/Gonorrhoea.aspx&quot; title=&quot;British Association for Sexual Health and HIV Web site&quot;>BASHH Web site</a>. </li>
</ul>
<p class=&quot;Disclaimer&quot;>Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on June 19, 2008. The information was verified by the guideline developer on October 20, 2008. This NGC summary was updates by ECRI Institute on October 1, 2012.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developers and/or BMJ Publishing Group's copyright restrictions. Reproduction and use of this guideline is permitted provided that (a) the original content is not changed or edited; and, (b) any content derived from the original guideline is acknowledged as that of the author(s) and responsible organizations.</p>
<p>Readers wishing to download and reproduce material for purposes other than personal study or education should contact BMJPG to seek permission first. Contact: BMJ Publishing Group, BMA House, Tavistock Square, WC1H 9JR, UK.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 22:38:04 Oct 02, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 02:21:37 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 377.495 (3)
  esindex: 0.011
  captures_list: 405.164
  CDXLines.iter: 20.69 (3)
  PetaboxLoader3.datanode: 48.84 (4)
  exclusion.robots: 0.537
  exclusion.robots.policy: 0.518
  RedisCDXSource: 1.42
  PetaboxLoader3.resolve: 498.536 (2)
  load_resource: 212.487
-->